Mesozooplankton community structure during summer months in the bay of Cádiz.

Mesozooplankton organisms (>250 μm) were sampled at two stations (inner and outer Bay) in the Bay of Cádiz between May and July 2008. Samples were analysed by means of a semi-automated technique in order to give a preliminary view of the mesoozooplankton community structure in the Bay, based on taxonomic diversity and biomass distribution among size classes. The abundance of organisms increased from May to July in accordance with the increase in temperature and Chlorophyll a (Chla) concentrations. Abundances were higher in the outer Bay station, where Chla concentrations are greater and the water column is more stable. The community changed from being meroplankton- to holoplankton-based due to an increase of Calanoida and especially Cladocera individuals (mainly Penilia avirostris), which are known to peak acutely in the summer. The analysis of Normalised Biomass-Size spectra revealed fairly steep slopes (average -1.3) and relatively high departures from steady state (r2 = 0.8 – 0.94), expectable in a coastal system such as the Bay of Cádiz were disturbance factors are introduced from benthic and tidal processes, together with anthropogenic pressure

Astroclimate at San Pedro M\'artir I: 2004-2008 Seeing Statistics from the TMT Site Testing Data

We present comprehensive seeing statistics for the San Pedro M\'artir site derived from the Thirty Meter Telescope site selection data. The observations were obtained between 2004 and 2008 with a Differential Image Motion Monitor (DIMM) and a Multi Aperture Scintillation Sensor (MASS) combined instrument (MASS--DIMM). The parameters that are statistically analised here are: whole atmosphere seeing -measured by the DIMM-; free atmosphere seeing --measured by the MASS--; and ground-layer seeing (GL) --difference between the total and free-atmosphere seeing--. We made a careful data coverage study along with statistical distributions of simultaneous MASS--DIMM seeing measurements, in order to investigate the nightly, monthly, seasonal, annual and global behaviour, as well as possible hourly seeing trends. Although this campaign covers five years, the sampling is uneven, being 2006 and 2007 the best sampled years in terms of seasonal coverage. The overall results yield a median seeing of 0.78 (DIMM), 0.37 (MASS) and 0.59 arcsec (GL). The strongest contribution to the whole atmosphere seeing comes, therefore, from a strong ground layer. We find that the best season is summer, while the worst one is winter, in accordance with previous studies. It is worth noting that the best yearly results are correlated with the best sampled years. The hourly analysis shows that there is no statistically significant tendency of seeing degradation towards dawn. The seeing values are slightly larger than those reported before. This may be caused by climate changes.Comment: Accepted for publication (2012 June 14) in MNRAS, 15 pages, 16 Figures, 8 Table

Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis

Objective: There is high prevalence of cigarette smoking in individuals with first-episode psychosis (FEP) prior to psychosis onset. The purpose of the study was to determine the impact of previous tobacco use with or without cannabis on first psychotic experiences in FEP and the impact of this use on age of onset of symptoms, including prodromes. Methods: Retrospective analyses from the naturalistic, longitudinal, multicentre, “Phenotype-Genotype and Environmental Interaction. Application of a Predictive Model in First Psychotic Episodes (PEPs)” Study. The authors analysed sociodemographic/clinical data of 284 FEP patients and 231 matched healthy controls, and evaluated first psychotic experiences of patients using the Symptom Onset in Schizophrenia Inventory. Results: FEP patients had significantly higher prevalence of tobacco, cannabis, and cocaine use than controls. The FEP group with tobacco use only prior to onset (N = 56) had more sleep disturbances (42.9% vs 18.8%, P = 0.003) and lower prevalence of negative symptoms, specifically social withdrawal (33.9% vs 58%, P = 0.007) than FEP with no substance use (N = 70), as well as lower prevalence of ideas of reference (80.4% vs 92.4%, P = 0.015), perceptual abnormalities (46.4% vs 67.4%, P = 0.006), hallucinations (55.4% vs 71.5%, P = 0.029), and disorganised thinking (41.1% vs 61.1%, P = 0.010) than FEP group with previous tobacco and cannabis use (N = 144). FEP patients with cannabis and tobacco use had lower age at first prodromal or psychotic symptom (mean = 23.73 years [SD = 5.09]) versus those with tobacco use only (mean = 26.21 [SD = 4.80]) (P = 0.011). Conclusions: The use of tobacco alone was not related to earlier age of onset of a first psychotic experience, but the clinical profile of FEP patients is different depending on previous tobacco use with or without cannabis. © 2021 The Author

Humanizar emprendiendo: homenaje a Rafael Alvira

Este cuaderno contiene "El Instituto y Rafael Alvira" "La carta 9 de Séneca" "Rafael Alvira: la castiza filosofía del hombre que vuelve" "Añoranza del humanismo necesario" "Una reflexión filosófica sobre lo económico: comentario a un texto de Rafael Alvira" "La dimensión societaria de la economía y de la empresa" "Sobre el espíritu aristocrático y el empresario: responsabilidades de ayer, responsabilidades de hoy" "Sobre el sistema de los derechos del hombre: el punto de vista de Charles Péguy" "El hogar familiar: espacio de lo eterno" "¿Filosofar con el martillo o con la empresa?" "Qué queremos decir cuando hablamos de desarrollo" "Tipologías de la información económico-financiera en la empresa. Valores y valoración" "Rafael Alvira y la Universidad de Montevideo" "Breve introducción al examen sistemático de “Cristianismo y empresarialidad”" "La realidad del poder en la familia y en la empresa familiar" "El todo y la parte. Alabanza de la sinécdoque" "Las raíces del liderazgo auténtico. Una fenomenología básica" "Algunas consideraciones sobre el poder político

Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma

Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype frequently associated with immunosuppression. Clinically, patients with PBL are characterized by poor outcome. The current understanding of the molecular pathogenesis is limited. A hallmark of PBL represents its plasmacytic differentiation with loss of B-cell markers and, in 60% of cases, its association with Epstein-Barr virus (EBV). Roughly 50% of PBLs harbor a MYC translocation. Here, we provide a comprehensive integrated genomic analysis using whole exome sequencing (WES) and genome-wide copy number determination in a large cohort of 96 primary PBL samples. We identify alterations activating the RAS-RAF, JAK-STAT, and NOTCH pathways as well as frequent high-level amplifications in MCL1 and IRF4. The functional impact of these alterations is assessed using an unbiased shRNA screen in a PBL model. These analyses identify the IRF4 and JAK-STAT pathways as promising molecular targets to improve outcome of PBL patients

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

Altres ajuts: Spanish AIDS Research Network; European Funding for Regional Development (FEDER).Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality